ReviewGlycoconjugate journal2012
Galectins and their ligands: negative regulators of anti-tumor immunity.
Review in Glycoconjugate journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 62 citations in OpenAlex.
- Serum soluble Tim‑3 is elevated in patients with cervical cancer and is higher in advanced clinical stages.Biomedical reports · 2025Article
- It's about TIME - Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma.Frontiers in immunology · 2025Review
- Galectin-3 and cancer immunotherapy: a glycobiological rationale to overcome tumor immune escape.Journal of experimental & clinical cancer research : CR · 2024Article
- Galectin-9 - ligand axis: an emerging therapeutic target for multiple myeloma.Frontiers in immunology · 2024Review
- The Importance of M1-and M2-Polarized Macrophages in Glioma and as Potential Treatment Targets.Brain sciences · 2023Review
- Galectin-3 expression in donor T cells reduces GvHD severity and lethality after allogeneic hematopoietic cell transplantation.Cell reports · 2023Article
- Hypoxia Controls the Glycome Signature and Galectin-8-Ligand Axis to Promote Protumorigenic Properties of Metastatic Melanoma.The Journal of investigative dermatology · 2023Article
- Molecular Cloning and Functional Characterization of Galectin-1 in Yellow Drum (International journal of molecular sciences · 2023Article
- Galectin-9 in cancer therapy: from immune checkpoint ligand to promising therapeutic target.Frontiers in cell and developmental biology · 2023Review
- Glycan-Lectin Interactions as Novel Immunosuppression Drivers in Glioblastoma.International journal of molecular sciences · 2022Review
- Targeting ZFP64/GAL-1 axis promotes therapeutic effect of nab-paclitaxel and reverses immunosuppressive microenvironment in gastric cancer.Journal of experimental & clinical cancer research : CR · 2022Article
- Enhanced Inhibitory Effect of DC-CIK Cells on Lung Adenocarcinoma via Anti-Tim-3 Antibody and Antiprogrammed Cell Death-1 Antibody and Possible Mechanism.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Antiproliferative and Antimicrobial Potentials of a Lectin fromMarine drugs · 2021Article
- Galectin-9 bridges human B cells to vascular endothelium while programming regulatory pathways.Journal of autoimmunity · 2021Article
- Galectin-9 and PSMB8 overexpression predict unfavorable prognosis in patients with AML.Journal of Cancer · 2021Article
- Overexpression of Galectin-1 and Galectin-3 in hepatocellular carcinoma.Liver research (Beijing, China) · 2020Article
- Combining inhibition of galectin-3 with and before a therapeutic vaccination is critical for the prostate-tumor-free outcome.Journal for immunotherapy of cancer · 2020Article
- The association between increasing levels of O-GlcNAc and galectins in the liver tissue of hibernating thirteen-lined ground squirrels (Ictidomys tridecemlineatus).Cell and tissue research · 2020Article
- Cherry Valley Duck Galectin-2 Plays an Essential Role in Avian PathogenicFrontiers in veterinary science · 2020Article
- The Association Between Immune Characteristic and Clinical Pathology in Chinese Patients with Adenocarcinoma of Esophagogastric Junction.Cancer management and research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Cytotoxic CD8(+) T cells are major players of anti-tumor immune responses, as their functional activity can limit tumor growth and progression. Data show that cytotoxic T cells efficiently control the proliferation of tumor cells through major histocompatibility complex class I-mediated mechanisms; nevertheless, the presence of tumor-infiltrating CD8(+) T cells in lesional tissue does not always correlate with better prognosis and increased survival of cancer patients. Similarly, adoptive transfer of tumor-specific cytotoxic T cells has only shown marginal improvement in life spans of patients with metastatic disease. In this report, we discuss experimental evidence showing that expression of tumor-derived galectins, galectin (Gal)-1, Gal-3 and Gal-9, and concomitant presence of their ligands on the surface of anti-tumor immunocytes directly compromise anti-tumor CD8(+) T cell immune responses and, perhaps, undermine the promise of adoptive CD8(+) T cell immunotherapy. Furthermore, we describe novel strategies designed to counteract Gal-1-, Gal-3- and Gal-9-mediated effects and highlight their targeting potential for creating more effective anti-tumor immune responses. We believe that Gal and their ligands represent an efficacious targeted molecular paradigm that warrants clinical evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.